Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.64 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.64 |
| ▸ | CDK9 | P50750 | 1/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.64 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.64 |
| ▸ | CDK4 | P11802 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522717 | 0.84 | CSNK1E (0.66) | CDK2CCNT1CCNA2CSNK1ECDK9 | |
| SCHEMBL409900 | 0.81 | CDK4 (0.66) | CDK2CSNK1ECDK4 | |
| SCHEMBL14561627 | 0.81 | — | — | |
| SCHEMBL14561630 | 0.80 | — | — | |
| SCHEMBL14561625 | 0.80 | — | — | |
| SCHEMBL4466628 | 0.79 | — | — | |
| SCHEMBL12023544 | 0.78 | CSNK1E (0.64) | CDK2CCNT1CCNA2CSNK1ECDK9 | |
| SCHEMBL14561028 | 0.77 | — | — | |
| SCHEMBL22342526 | 0.77 | ALDH1A1 (0.61) | CSNK1E | |
| SCHEMBL5411874 | 0.77 | MAPK1 (0.58) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | CDK2 58/4885CCNT1 370/4885CCNA2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.